Genentech Reports High-Dose Ocrelizumab Fails to Show Additional Benefit in Relapsing MS

Published Date: 09 Apr 2025

The company's phase 3 MUSETTE trial reported that an increased ocrelizumab dose did not further slow disability progression but reinforced the efficacy of the approved 600 mg dose.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Lesser-known lobular breast cancer on the rise in U.S. women

2.

Study finds that AI is better at forecasting the risk of developing cancer.

3.

Kate Middleton and Remission: Oncologists Weigh In

4.

According to the Lancet, proton beam therapy may shorten the course of treatment for patients with breast cancer.

5.

What Role Should Genomic Classifier Testing Play in Prostate Cancer?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot